Virtual Library

Start Your Search

Hongyun Zhao

Author of

  • +

    P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.01-109 - Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer (ID 13616)

      16:45 - 18:00  |  Presenting Author(s): Hongyun Zhao

      • Abstract
      • Slides


      EGFR-TKI plus bevacizumab (anti-VEGF) has brought significant progression-free survival (PFS) improvement for advanced NSCLC patients (pts) as first-line therapy compared to EGFR-TKI alone (16.0 vs. 9.7 months, HR 0.41, Lancet Oncol, 15(11):1236-1244). Apatinib, a TKI that selectively inhibits VEGFR-2, has shown strong antitumor activity in both preclinical and clinical studies in NSCLC. This phase I study aims to evaluate the safety and efficacy of Gefitinib plus Apatinib in the first line setting.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Treatment-naïve advanced NSCLC pts with EGFR 19 Del or 21 L858R mutation were eligible. Two prespecified groups were designed: Cohort 1: Apatinib 500mg QD PO + Gefitinib 250mg QD PO; Cohort 2: Apatinib 250mg QD PO + Gefitinib 250mg QD PO. Pharmacokinetics (PK) profile of Apatinib plus Gefitinib was also evaluated. 6 pts in each cohort should be enrolled for PK analysis.

      4c3880bb027f159e801041b1021e88e8 Result

      From July 2016 to April 2017, 12 pts were enrolled. Most common AEs were rash (91.7%, 11/12), diarrhea (66.7%, 8/12), proteinuria (58.3%, 7/12), hypertension (25.0%, 3/12), and hand-foot-skin reaction (8.3%, 1/12). And most of AEs were grade 1-2. SAE was observed in 1 case with grade 3 hypertension (8.3%). The PK parameters in this combination setting were similar to those of single agent from the previous literature reports (Table 1). Among all evaluable patients, ORR was 83.3% (10/12), and DCR was 91.7% (11/12). Median PFS was 19.0 months (95% CI 0.0–43.9) in the Apatinib (500mg) + Gefitinib group and 13.4 months (13.0–13.8) in the Apatinib (250mg) + Gefitinib group (P=0.657).

      Table 1. Pharmacokinetic parameters (geometric mean, SD) of apatinib and gefitinib

      Apatinib 250mg Apatinib 500mg Gefitinib 250mg
      Cmax (ng/ml) 446(283) 499(257) 468(28)
      Cmaxmulti (ng/ml) 415(184) 603(438) 469(134)
      Tmax (h) 2.6(1.0) 2.8(1.9) 3.9(1.2)
      AUC0-24 (ng·h/ml) 3315(2367) 4155(2564) 3330(852)
      AUC0-24multi(ng·h/ml) 4875(4439) 4914(3898) 8132(2311)
      8eea62084ca7e541d918e823422bd82e Conclusion

      Apatinib (500mg) in combination with Gefitinib (250mg) shows a manageable tolerability profile and prolonged PFS tendency for EGFR-mutant NSCLC patients in first-line treatment setting. Clinical trial information: NCT02824458


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.